Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Tidewater Inc (TDW) Price & Performance

Adaptive Biotechnologies CorpTrade
Tidewater IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Tidewater Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.9 (market cap $4.04B), while Tidewater Inc trades at $91.14 (market cap $4.54B). The key difference: Adaptive Biotechnologies Corp and Tidewater Inc are close in size by market cap. Which is the better fit depends on your goals.

ADPTTDW
Market Cap
$4.04B$4.54B
Sector
HealthUtilities
52-Week High
$25.45$91.20
52-Week Low
$12.30$47.29
Enterprise Value
$4.10B$4.58B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.

Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.

Tidewater Inc

Tidewater (TDW) trades at $91.86, up 2.49% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 earnings of $0.43 per share, beating estimates (Zacks, August 3, 2026), though it missed expectations in prior quarters. Revenue for the quarter was $342.3 million, with net income margins around 18%. Analyst sentiment is mixed, with 26.92% recommending Buy and 57.7% Hold.

Outlook: Strong day rates and utilization support revenue growth, but earnings misses and Middle East operational costs pose risks. The stock's valuation (P/E 18.5) is reasonable, but investors face volatility from oil market exposure and execution challenges. Upside depends on sustained operational improvements and cost management.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Tidewater Inc

Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.

Read more on TDW